TR201819828T4 - Anti-fosfolipaz d4 antikoru. - Google Patents
Anti-fosfolipaz d4 antikoru. Download PDFInfo
- Publication number
- TR201819828T4 TR201819828T4 TR2018/19828T TR201819828T TR201819828T4 TR 201819828 T4 TR201819828 T4 TR 201819828T4 TR 2018/19828 T TR2018/19828 T TR 2018/19828T TR 201819828 T TR201819828 T TR 201819828T TR 201819828 T4 TR201819828 T4 TR 201819828T4
- Authority
- TR
- Turkey
- Prior art keywords
- phospholipase
- antibody
- pld4
- antigen
- binds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012018266 | 2012-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201819828T4 true TR201819828T4 (tr) | 2019-01-21 |
Family
ID=47748721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/19828T TR201819828T4 (tr) | 2012-01-31 | 2013-01-31 | Anti-fosfolipaz d4 antikoru. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9944715B2 (https=) |
| EP (2) | EP2809683B1 (https=) |
| JP (4) | JP6118345B2 (https=) |
| KR (1) | KR102098413B1 (https=) |
| CN (2) | CN104284903B (https=) |
| AU (2) | AU2013215886B2 (https=) |
| CA (1) | CA2863009C (https=) |
| DK (2) | DK3431504T3 (https=) |
| ES (2) | ES2694165T3 (https=) |
| HU (2) | HUE054362T2 (https=) |
| IL (1) | IL233794B (https=) |
| PL (2) | PL2809683T3 (https=) |
| PT (1) | PT2809683T (https=) |
| TR (1) | TR201819828T4 (https=) |
| WO (1) | WO2013115410A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2809683T3 (pl) * | 2012-01-31 | 2019-03-29 | Sbi Biotech Co., Ltd. | Przeciwciało przeciwko fosfolipazie D4 |
| PL3027656T3 (pl) * | 2013-07-30 | 2019-10-31 | Sbi Biotech Co Ltd | Lek zawierający przeciwciało anty-fosfolipazowe D4 |
| CN109535254B (zh) * | 2013-12-24 | 2022-06-24 | 安斯泰来制药株式会社 | 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物 |
| US10759859B2 (en) | 2016-01-14 | 2020-09-01 | Bps Bioscience, Inc. | Anti-PD-1 antibodies and uses thereof |
| AU2017231833B2 (en) | 2016-03-10 | 2024-03-14 | Viela Bio, Inc. | ILT7 binding molecules and methods of using the same |
| CN105624325B (zh) * | 2016-03-31 | 2019-06-11 | 北京泱深生物信息技术有限公司 | 肺腺癌的诊治标记物 |
| PL3691692T3 (pl) * | 2017-10-14 | 2021-07-19 | Abbvie Inc. | Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania |
| CN110042123B (zh) * | 2019-01-07 | 2023-01-17 | 西北农林科技大学 | 一种通过诱导表达zfp57提高牛体细胞克隆效率的方法 |
| WO2025085746A1 (en) * | 2023-10-18 | 2025-04-24 | Immunorx Pharma Inc. | Humanized anti-s100a9 antibody |
| CN119120388A (zh) * | 2024-10-22 | 2024-12-13 | 江苏亲科生物研究中心有限公司 | 一种pdpfl单克隆抗体及其试剂盒的制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098015B2 (en) * | 1999-06-11 | 2006-08-29 | Millennium Pharmaceuticals, Inc. | 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor |
| WO2004050850A2 (en) | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to phospholipase a2 and uses thereof |
| SI1674111T1 (sl) * | 2004-07-09 | 2011-02-28 | Chugai Pharmaceutical Co Ltd | Protitelo proti glipikanu 3 |
| PL2809683T3 (pl) * | 2012-01-31 | 2019-03-29 | Sbi Biotech Co., Ltd. | Przeciwciało przeciwko fosfolipazie D4 |
| PL3027656T3 (pl) * | 2013-07-30 | 2019-10-31 | Sbi Biotech Co Ltd | Lek zawierający przeciwciało anty-fosfolipazowe D4 |
-
2013
- 2013-01-31 PL PL13705843T patent/PL2809683T3/pl unknown
- 2013-01-31 AU AU2013215886A patent/AU2013215886B2/en active Active
- 2013-01-31 KR KR1020147023620A patent/KR102098413B1/ko active Active
- 2013-01-31 US US14/375,266 patent/US9944715B2/en active Active
- 2013-01-31 TR TR2018/19828T patent/TR201819828T4/tr unknown
- 2013-01-31 HU HUE18188036A patent/HUE054362T2/hu unknown
- 2013-01-31 CA CA2863009A patent/CA2863009C/en active Active
- 2013-01-31 JP JP2014554166A patent/JP6118345B2/ja active Active
- 2013-01-31 CN CN201380018285.5A patent/CN104284903B/zh active Active
- 2013-01-31 PT PT13705843T patent/PT2809683T/pt unknown
- 2013-01-31 DK DK18188036.0T patent/DK3431504T3/da active
- 2013-01-31 EP EP13705843.4A patent/EP2809683B1/en active Active
- 2013-01-31 EP EP18188036.0A patent/EP3431504B1/en active Active
- 2013-01-31 PL PL18188036T patent/PL3431504T3/pl unknown
- 2013-01-31 HU HUE13705843A patent/HUE041552T2/hu unknown
- 2013-01-31 ES ES13705843.4T patent/ES2694165T3/es active Active
- 2013-01-31 DK DK13705843.4T patent/DK2809683T3/en active
- 2013-01-31 WO PCT/JP2013/052781 patent/WO2013115410A2/en not_active Ceased
- 2013-01-31 ES ES18188036T patent/ES2873035T3/es active Active
- 2013-01-31 CN CN202011128007.3A patent/CN112442128B/zh active Active
-
2014
- 2014-07-24 IL IL233794A patent/IL233794B/en active IP Right Grant
-
2017
- 2017-03-24 JP JP2017058867A patent/JP2017155045A/ja active Pending
-
2018
- 2018-02-08 AU AU2018200934A patent/AU2018200934B2/en active Active
- 2018-03-02 US US15/910,206 patent/US10336834B2/en active Active
- 2018-11-27 JP JP2018220873A patent/JP6830471B2/ja active Active
-
2020
- 2020-10-28 JP JP2020180164A patent/JP7244102B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201819828T4 (tr) | Anti-fosfolipaz d4 antikoru. | |
| EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
| CL2014000574A1 (es) | Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano. | |
| EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
| EA201390933A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
| PL3181581T3 (pl) | Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klierens antygenu | |
| CR20140585A (es) | Proteinas de union a antigeno st2 | |
| CL2015002756A1 (es) | Moléculas fc biespecíficas | |
| SA517381663B1 (ar) | أجسام مضادة تستهدف مولد ضد نضج لخلايا وطرق استخدامها b | |
| MA34091B1 (fr) | Anticorps anti-cd40 | |
| DK3331910T3 (da) | Monoklonale antistoffer mod humant b-cellemodningsantigen (bcma) | |
| PT3016681T (pt) | Anticorpos humanizados ou quiméricos cd3 | |
| MX377196B (es) | Proteinas de fusion de inmunoglobulina de la proteina alfa reguladora de señal (sirp-alfa). | |
| IL229618B (en) | Isolated antibody that binds fcrn | |
| EA201891339A1 (ru) | Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб | |
| EP3702372A3 (en) | Anti-cd40 human antibodies | |
| CL2016000460A1 (es) | Proteínas de unión al antígeno gitr | |
| NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
| CO7111294A2 (es) | Anticuerpo anti-fgfr2 | |
| BR112016014731A2 (pt) | Anticorpos anti-baff | |
| MX352599B (es) | Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano. | |
| EA201990672A1 (ru) | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты | |
| UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ | |
| EP3029069A4 (en) | Anti-human cd26 monoclonal antibody or antigen-binding fragment thereof | |
| EA201291065A1 (ru) | Антитела против vla-4 |